Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D’Amour as Chief Scientific Officer BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and...

Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, Massachusetts BROOKLYN, N.Y., June 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and...